Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab As Frontline Therapy for Adults with CD-20 Positive Acute Lymphoblastic Leukemia (ALL)

被引：0

作者：

Jabbour, Elias ^{[1
]}

Kantarjian, Hagop M. ^{[1
]}

Thomas, Deborah A. ^{[1
]}

Sasaki, Koji ^{[1
]}

Garcia-Manero, Guillermo ^{[1
]}

Garris, Rebecca ^{[1
]}

Cortes, Jorge E. ^{[1
]}

Kadia, Tapan M. ^{[1
]}

Ravandi, Farhad ^{[1
]}

Verstovsek, Srdan ^{[1
]}

O'Brien, Susan ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[1] Phase II Study Of The Hyper-CVAD Regimen In Combination With Ofatumumab As Frontline Therapy For Adults With CD-20 Positive Acute Lymphoblastic Leukemia (ALL)
Jabbour, Elias
Hagop, Kantarjian
Thomas, Deborah
Garcia-Manero, Guillermo
Hoehn, Daniela
Garris, Rebecca
Faderl, Stefan H.
Cortes, Jorge E.
Kadia, Tapan M.
Ravandi, Farhad
Verstovsek, Srdan
O'Brien, Susan
BLOOD, 2013, 122 (21)
[2] Phase II study of the hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with CD-20 positive ALL.
Jabbour, Elias
Kantarjian, Hagop M.
Thomas, Deborah A.
Garcia-Manero, Guillermo
Aad, Simon Abi
Garris, Rebecca
Cortes, Jorge E.
Kadia, Tapan M.
Ravandi, Farhad
Verstovsek, Srdan
O'Brien, Susan Mary
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[3] Phase II Study of the Frontline Hyper-CVAD in Combination with Ofatumumab for Adult Patients (pts) with CD-20 Positive Acute Lymphoblastic Leukemia (ALL)
Sasaki, Koji
Koller, Paul B.
Kantarjian, Hagop M.
Thomas, Deborah A.
Khouri, Maria R.
Garcia-Manero, Guillermo
Garris, Rebecca
Cortes, Jorge E.
Schroeder, Heather
Chahoud, Jad
Kadia, Tapan
Ravandi, Farhad
Verstovsek, Srdan
Daver, Naval
Jain, Nitin
Konopleva, Marina
O'Brien, Susan
Jabbour, Elias
BLOOD, 2015, 126 (23)
[4] Frontline Ofatumumab in Combination with Hyper-CVAD for Adult Patients with CD-20 Positive Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial
Sasaki, Koji
Kantarjian, Hagop M.
Ravandi, Farhad
Daver, Naval
Kadia, Tapan M.
Khouri, Rita B.
Alvarado, Yesid
Burger, Jan A.
Thomas, Deborah A.
Garcia-Manero, Guillermo
DiNardo, Courtney D.
Pemmaraju, Naveen
Short, Nicholas J.
Schroeder, Heather
Garris, Rebecca
Bose, Prithviraj
Jain, Nitin
Naqvi, Kiran
Wierda, William G.
Verstovsek, Srdan
Cortes, Jorge E.
Konopleva, Marina
O'Brien, Susan M.
Jabbour, Elias J.
BLOOD, 2016, 128 (22)
[5] Hyper-CVAD Plus Ofatumumab as Frontline Therapy for Adults with CD20 Positive Acute Lymphoblastic Leukemia
Yilmaz, Musa
Kantarjian, Hagop
Ravandi, Farhad
Thomas, Deborah
Khouri, Maria
Garcia-Manero, Guillermo
Garris, Rebecca
Cortes, Jorge
Short, Nicholas
Sasaki, Koji
Issa, Ghayas
Koller, Paul
Schroeder, Heather
Kadia, Tapan
Verstovsek, Srdan
Daver, Naval
Jain, Nitin
Konopleva, Marina
O'Brien, Susan
Jabbour, Elias
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S185 - S185
[6] Updated results from the phase II study of hyper-CVAD in combination with ofatumumab as frontline therapy for adults with CD20 positive (CD20+) acute lymphoblastic leukemia (ALL).
Issa, Ghayas C.
Kantarjian, Hagop M.
Ravandi, Farhad
Thomas, Deborah A.
Khouri, Maria
Garcia-Manero, Guillermo
Garris, Rebecca S.
Cortes, Jorge E.
Short, Nicholas James
Sasaki, Koji
Schroeder, Heather M.
Kadia, Tapan M.
Verstovsek, Srdan
Daver, Naval Guastad
Jain, Nitin
Konopleva, Marina
O'Brien, Susan Mary
Jabbour, Elias
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[7] Frontline Ofatumumab with Hyper-CVAD in CD20+Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial
Maiti, Abhishek
Kantarjian, Hagop
Ravandi, Farhad
Thomas, Deborah
Khouri, Maria
Garcia-Manero, Guillermo
Garris, Rebecca
Cortes, Jorge
Short, Nicholas
Sasaki, Koji
Issa, Ghayas
Koller, Paul
Schroeder, Heather
Kadia, Tapan
Verstovsek, Srdan
Daver, Naval
Jain, Nitin
Konopleva, Marina
O'Brien, Susan
Jabbour, Elias
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S256 - S257
[8] Hyper-CVAD Plus Ofatumumab As Frontline Therapy in CD20+Acute Lymphoblastic Leukemia: Updated Results of a Phase II Trial
Maiti, Abhishek
Kantarjian, Hagop M.
Ravandi, Farhad
Khouri, Maria
Thomas, Deborah A.
Garcia-Manero, Guillermo
Garris, Rebecca
Cortes, Jorge E.
Short, Nicholas J.
Jain, Nitin
Bose, Prithviraj
Verstovsek, Srdan
Konopleva, Marina
Sasaki, Koji
Issa, Ghayas C.
Ghosn, Marie
Schroeder, Heather M.
Kadia, Tapan
Daver, Naval
O'Brien, Susan M.
Jabbour, Elias J.
BLOOD, 2017, 130
[9] A phase 2 study of hyper-CVAD plus ofatumumab as frontline therapy in CD20+acute lymphoblastic leukemia (ALL): Updated results.
Bazarbachi, Abdul Hamid
Yilmaz, Musa
Ravandi, Farhad
Thomas, Deborah A.
Khouri, Maria
Garcia-Manero, Guillermo
Garris, Rebecca S.
Cortes, Jorge E.
Short, Nicholas James
Sasaki, Koji
Issa, Ghayas C.
Koller, Paul B.
Kadia, Tapan M.
Verstovsek, Srdan
Daver, Naval Guastad
Jain, Nitin
Konopleva, Marina
O'Brien, Susan Mary
Jabbour, Elias
Kantarjian, Hagop M.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[10] Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab (HCVAD-O) As Frontline Therapy for Adult Patients (pts) with CD20-Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Richard-Carpentier, Guillaume
Kantarjian, Hagop M.
Konopleva, Marina Y.
Patel, Keyur P.
Roberts, Kathryn G.
Gu, Zhaohui
Ravandi, Farhad
Jain, Nitin
Short, Nicholas J.
Garcia-Manero, Guillermo
Schroeder, Heather M.
Kwari, Monica
Garris, Rebecca
Khouri, Rita
Jones, Mike
Loiselle, Christopher
Cortes, Jorge E.
Sasaki, Koji
Issa, Ghayas C.
Kadia, Tapan M.
DiNardo, Courtney D.
Verstovsek, Srdan
Daver, Naval G.
Mullighan, Charles G.
O'Brien, Susan M.
Jabbour, Elias
BLOOD, 2019, 134

← 1 2 3 4 5 →